T1D Autoantibodies: room for improvement?

Current Opinion in Endocrinology, Diabetes, and Obesity
Liping YuAndrea K Steck

Abstract

Type 1 diabetes (T1D) is now predictable by measuring major islet autoantibodies (IAbs) against insulin and other pancreatic β cells proteins including GAD65 (GADA), islet antigen 2 (IA-2A), and zinc transporter 8 (ZnT8A). The assay technology for IAbs has made great progress; however, several important aspects still need to be addressed and improved. Currently a radio-binding assay has been well established as the 'gold' standard assay for all four IAbs. New generation of nonradioactive IAb assay with electrochemiluminescence technology has been shown to further improve sensitivity and disease specificity. Recently, multiplexed assays have opened the possibility of more efficient screening in large populations. Identification of potential new autoantibodies to neo-antigens or neo-epitopes posttranslational modification is a new important field to be explored. Individuals having a single positive autoantibody are at low risk for progression to T1D, whereas individuals expressing two or more positive autoantibodies, especially on multiple tests over time, have nearly 100% risk of developing clinical T1D when followed for over two decades. More efficient and cost effective IAb assays will hopefully lead to point-of-care screening...Continue Reading

References

Apr 30, 2003·Diabetes·Polly J BingleyPatricia W Mueller
Nov 2, 2005·The Journal of Experimental Medicine·Stuart I ManneringAnthony W Purcell
Mar 1, 2007·Diabetes Care·Kendra VehikDana Dabelea
Sep 28, 2010·Diabetologia·M SchlosserUNKNOWN Participating Laboratories
Jun 20, 2013·JAMA : the Journal of the American Medical Association·Anette G ZieglerGeorge S Eisenbarth
Sep 17, 2013·Pediatric Diabetes·Helena Elding LarssonUNKNOWN TEDDY Study Group
Jan 7, 2015·Diabetes Technology & Therapeutics·Dongmei MiaoUNKNOWN Type 1 Diabetes TrialNet Study Group
Aug 8, 2015·Pediatric Diabetes·Patricia D GesualdoJudith Baxter
Sep 17, 2015·Diabetes Technology & Therapeutics·Polly J BingleyUNKNOWN TrialNet Study Group
Oct 11, 2015·Proceedings of the National Academy of Sciences of the United States of America·Niyun JinJohn W Kappler
Mar 19, 2016·Diabetes Technology & Therapeutics·Andrea K SteckUNKNOWN TrialNet Study Group
Jul 28, 2016·Diabetes Care·Alexandra FoutsUNKNOWN Type 1 Diabetes TrialNet Study Group
Aug 24, 2016·Diabetes Technology & Therapeutics·Anette-G ZieglerPeter Achenbach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.